Literature DB >> 30683709

Suspected Hereditary Cancer Syndromes in Young Patients: Heterogeneous Clinical and Genetic Presentation of Colorectal Cancers.

Claudia Maletzki1, Maja Hühns2, Ingrid Bauer3, Friedrich Prall2, Christian Junghanss1, Larissa Henze4.   

Abstract

Colorectal cancer (CRC) is rare in young patients without a confirmed family history of cancer. Reports of an increased prevalence of POLD1/POLE mutations in young patients with colorectal cancer have raised awareness and support routine genetic testing for patients with early-onset tumors. In cases of CRC without proven MMR-germline mutation, molecular analyses are warranted to confirm or rule out other familial CRC syndromes. This article describes the cases of two young male patients, who presented with locally advanced and metastatic CRC, and reports the results of the germline mutational analyses done for both patients. These cases demonstrate the importance of special care and molecular diagnostic procedures for young patients with CRC. KEY POINTS: Patients with colorectal cancer who are younger than 50 years at initial diagnosis (early onset) should routinely undergo genetic testing.Early- and very-early-onset patients (younger than 40 years) with absence of microsatellite instability should be considered for tumor mutation burden testing and/or DNA polymerase proofreading mutation.The mutational signature of HSP110 within mismatch repair deficiency-related tumors may help to identify patients likely to benefit from 5-fluorouracil-based chemotherapy.Intensified, maintained, and specific surveillance may help to reduce secondary tumor progression. © AlphaMed Press 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30683709      PMCID: PMC6656443          DOI: 10.1634/theoncologist.2018-0614

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  27 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Authors:  Enric Domingo; Luke Freeman-Mills; Emily Rayner; Mark Glaire; Sarah Briggs; Louis Vermeulen; Evelyn Fessler; Jan Paul Medema; Arnoud Boot; Hans Morreau; Tom van Wezel; Gerrit-Jan Liefers; Ragnhild A Lothe; Stine A Danielsen; Anita Sveen; Arild Nesbakken; Inti Zlobec; Alessandro Lugli; Viktor H Koelzer; Martin D Berger; Sergi Castellví-Bel; Jenifer Muñoz; Marco de Bruyn; Hans W Nijman; Marco Novelli; Kay Lawson; Dahmane Oukrif; Eleni Frangou; Peter Dutton; Sabine Tejpar; Mauro Delorenzi; Rachel Kerr; David Kerr; Ian Tomlinson; David N Church
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-07-20

Review 3.  Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.

Authors:  Cecilia Guastadisegni; Mauro Colafranceschi; Laura Ottini; Eugenia Dogliotti
Journal:  Eur J Cancer       Date:  2010-06-04       Impact factor: 9.162

4.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.

Authors:  I Saeterdal; J Bjørheim; K Lislerud; M K Gjertsen; I K Bukholm; O C Olsen; J M Nesland; J A Eriksen; M Møller; A Lindblom; G Gaudernack
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

5.  Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Authors:  K Chang; J A Willis; J Reumers; M W Taggart; F A San Lucas; S Thirumurthi; P Kanth; D A Delker; C H Hagedorn; P M Lynch; L M Ellis; E T Hawk; P A Scheet; S Kopetz; J Arts; J Guinney; R Dienstmann; E Vilar
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

6.  Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer.

Authors:  Lucía Pérez-Carbonell; Clara Ruiz-Ponte; Carla Guarinos; Cristina Alenda; Artemio Payá; Alejandro Brea; Cecilia M Egoavil; Adela Castillejo; Victor M Barberá; Xavier Bessa; Rosa M Xicola; María Rodríguez-Soler; Cristina Sánchez-Fortún; Nuria Acame; Sergi Castellví-Bel; Virgínia Piñol; Francesc Balaguer; Luis Bujanda; María-Luisa De-Castro; Xavier Llor; Montserrat Andreu; Angel Carracedo; José-Luis Soto; Antoni Castells; Rodrigo Jover
Journal:  Gut       Date:  2011-08-25       Impact factor: 23.059

7.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

Authors:  Harvey A Risch; John R McLaughlin; David E C Cole; Barry Rosen; Linda Bradley; Isabel Fan; James Tang; Song Li; Shiyu Zhang; Patricia A Shaw; Steven A Narod
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

8.  Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.

Authors:  Yvette Schwitalle; Michael Linnebacher; Eva Ripberger; Johannes Gebert; Magnus von Knebel Doeberitz
Journal:  Cancer Immun       Date:  2004-11-25

Review 9.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

Authors:  Alexander Liede; Beth Y Karlan; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-02-15       Impact factor: 44.544

Review 10.  Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome).

Authors:  Daniel D Buchanan; Christophe Rosty; Mark Clendenning; Amanda B Spurdle; Aung Ko Win
Journal:  Appl Clin Genet       Date:  2014-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.